Chronic Urticaria Biologic Cost Calculator Korea

Estimate a South Korean omalizumab budget for chronic spontaneous urticaria while keeping the MFDS indication, HIRA reimbursement criteria, UAS7 tracking, and provider-confirmed costs separate.

Health cost scenario inputs

Enter Korea-related chronic care, eldercare, therapy, procedure, fertility, diagnostic, or medical tourism assumptions. Results are simplified planning estimates.

Treatment cost over period

₩4,684,632

Monitoring or support cost

₩0

Increase reserve

₩468,463

Planning window cost

₩5,153,095

12 months

This shared English calculator is a simplified South Korea budget view, not the dedicated Korean dose counter. MFDS item 201602975 currently displays Xolair 150 mg, product code 653602891, at KRW 216,755 for September 1, 2025 through August 31, 2027. MFDS item 202400492 displays the separate Xolair 300 mg syringe, code 653603541, at KRW 360,356 from October 1, 2025. The approved chronic-urticaria use is age 12 or older, inadequate response to H1 antihistamines, and 150 mg or 300 mg subcutaneously every four weeks. A 52-week plan is 13 administrations: KRW 2,817,815 at 150 mg or KRW 4,684,628 at 300 mg before other charges. HIRA Notice No. 2025-224, effective January 1, 2026, enumerates allergic-asthma reimbursement criteria for omalizumab and requires full patient payment outside those criteria; the July 2026 update did not add chronic urticaria. UAS7 is a 0-42 symptom diary, not a diagnosis or coverage rule. Replace every default with the actual provider and payer confirmation. This is not medical advice, a prescription, a coverage decision, or an insurer guarantee.

Related calculators

South Korea rules checked July 27, 2026

Separate the Korean indication from reimbursement before budgeting

Chronic spontaneous urticaria, also called chronic idiopathic urticaria in the Korean product label, causes recurrent wheals, itching, and sometimes angioedema for six weeks or longer. Omalizumab is an add-on biologic option when H1-antihistamine therapy does not control symptoms, but an approved indication is not the same as a Korean National Health Insurance reimbursement decision.

The current MFDS label for Xolair includes patients aged 12 or older with chronic idiopathic urticaria that is inadequately controlled by H1 antihistamines. It lists 150 mg or 300 mg by subcutaneous injection every four weeks and says the need for continued treatment should be reassessed periodically. The current HIRA omalizumab reimbursement criteria, however, enumerate severe persistent allergic asthma. They state that drug cost outside the listed criteria is paid in full by the patient even when use remains within the approved label.

For a chronic-urticaria plan, use full patient payment as the default. Enter a lower covered copay only when the treating institution has confirmed a different reimbursed indication or claim route for the actual case. Neither this page nor a UAS7 score grants coverage.

What UAS7 records—and what it cannot decide

UAS7 is a seven-day symptom diary. Each day, the number of wheals and the intensity of itching are each scored from zero to three. The daily scores are summed over seven days, producing a total from zero to 42. International urticaria guidance recommends it for assessing disease activity, and it is useful when discussing response over time with a clinician.

Seven-day urticaria activity

UAS7 = seven-day wheal subtotal + seven-day itch subtotal

0

Urticaria-free

Symptom-tracking band.

1–6

Well controlled

Symptom-tracking band.

7–15

Mild activity

Symptom-tracking band.

16–27

Moderate activity

Symptom-tracking band.

28–42

Severe activity

Symptom-tracking band.

Does a high UAS7 establish eligibility?

No. UAS7 does not diagnose chronic spontaneous urticaria, select the dose, authorize reimbursement, or determine when to start or stop a biologic. A clinical review still needs the symptom history, angioedema risk, medicine names and doses, adherence, alternative diagnoses, comorbidities, pregnancy considerations, and safety factors. Bring the completed diary to the appointment rather than treating a threshold as an insurance rule.

Current Korean Xolair price anchors

The dedicated Korean calculator uses the prices displayed on the current MFDS product pages. Xolair prefilled syringe 150 mg, Korean product code 653602891, is shown at KRW 216,755 for the period from September 1, 2025 through August 31, 2027. Xolair prefilled syringe 300 mg, product code 653603541, is shown at KRW 360,356 from October 1, 2025. These current figures replace the older KRW 271,700 launch price sometimes repeated in Korean cost articles.

Current Korean Xolair public price anchors and 12-month drug cost
ProductKorean code and displayed periodPer administration13 administrations
Xolair 150 mg PFS653602891 · 2025-09-01 to 2027-08-31KRW 216,755KRW 2,817,815
Xolair 300 mg PFS653603541 · from 2025-10-01KRW 360,356KRW 4,684,628

These are drug-price anchors, not a guaranteed hospital invoice. A provider may separately bill consultation, injection, observation, testing, and other medicines. The Korean calculator therefore lets the user replace the anchor with a provider-confirmed amount and add each separate item without double counting.

Why a 12-month plan contains 13 injections

Every four weeks is not the same as once per calendar month. The Korean calculator converts the planning months to weeks using 52 weeks per year, includes the administration at the start of the interval, and excludes an administration exactly at the ending boundary. This gives four administrations in three months, seven in six months, and 13 in 12 months.

3 months

4 administrations

Useful for a short consultation budget window.

6 months

7 administrations

Shows a roughly 24-week planning window.

12 months

13 administrations

Prevents the common once-per-month undercount.

The planning period is not a stop date

The MFDS label calls for periodic reassessment of continued treatment need. A three-, six-, or 12-month selection is only a household budget window. Response, recurrence, adverse effects, preferences, and the treating clinician determine the actual course. Do not stop or extend treatment because the budget window ends.

Build a provider-verified Korean budget

  1. Complete seven days of wheal and itch scores and keep the daily diary for the consultation.
  2. Record age, symptom duration, and whether inadequate response to H1 antihistamine therapy has been confirmed by the care team.
  3. Enter the clinician-provided 150 mg or 300 mg plan and the intended planning period. Dose is not a consumer price choice.
  4. Keep full patient payment unless the institution confirms a covered claim for the actual case. Ask for the diagnosis, product code, and copay basis in writing.
  5. Add consultation, injection, observation, testing, antihistamines, and other medicines only when they are not already included in the drug quote.
  6. Add travel and time cost per visit. Four-week dosing can make these household costs material for long-distance care.
  7. Deduct only reimbursement already confirmed by a private insurer, employer, patient program, or other payer. Do not infer a percentage from a policy name.

Ask the Korean provider

  • Which dose, product, and Korean product code will be used?
  • Is the drug covered, full patient payment, or non-covered?
  • Are consultation, injection, and observation included?
  • Does observation time or cost differ for early doses?
  • Which tests and medicines are billed separately?

Ask the private insurer

  • Is full patient payment for this drug reimbursable?
  • What outpatient cap and per-visit deductible apply?
  • Which itemized bill, prescription, or medical letter is needed?
  • How much annual benefit remains after prior claims?
  • Can the answer be provided in writing before treatment?

Safety and benefit boundaries

  • Anaphylaxis has been reported with omalizumab, including after long exposure. Treatment must start under professional direction with a plan for recognizing and treating severe allergic reactions.
  • Swelling of the tongue or throat, breathing difficulty, faintness, or rapidly progressive systemic symptoms require emergency care, not a cost calculation.
  • The Korean annual out-of-pocket ceiling applies to eligible covered copays. Do not automatically apply it to full-patient-payment drug cost or non-covered services.
  • A private indemnity policy, manufacturer program, or employer plan may have contract-specific exclusions, caps, and documents. Use zero support until an amount is confirmed.
  • Prices and reimbursement criteria can change. Recheck the product code, effective date, HIRA criteria, and provider quote before the next prescription.

Frequently asked questions

Is Xolair approved for chronic urticaria in South Korea?

Yes. The MFDS product information includes H1-antihistamine-inadequate chronic idiopathic urticaria in adults and adolescents aged 12 or older. Approval does not by itself establish NHIS reimbursement.

Why does the Korean calculator start at 100% patient payment?

The current HIRA omalizumab criteria enumerate severe persistent allergic asthma and state that approved-label use outside the listed criteria is paid in full by the patient.

Does UAS7 of 16 or more make the drug reimbursable?

No. UAS7 tracks symptoms. Do not confuse criteria proposed in older assessment materials with the reimbursement criteria currently in force.

Why is annual four-week dosing counted as 13 administrations?

A year has 52 weeks, and 52 divided by four is 13. Counting only one dose per calendar month understates a true four-week schedule.

Is 300 mg priced as two 150 mg syringes?

No. MFDS currently lists a separate 300 mg prefilled syringe at KRW 360,356. The Korean calculator uses that product rather than doubling the 150 mg price.

Can this page estimate private insurance reimbursement?

Not reliably. Korean contracts vary by issue date, outpatient cap, deductible, and handling of full-patient-payment drugs. Enter only a total already confirmed for the actual policy.

Primary sources

The figures and rule boundaries above were checked against the following primary Korean and professional sources on July 27, 2026. Recheck them when planning a later course.
This guide is not a diagnosis, prescription, reimbursement decision, or substitute for advice from the treating clinician and billing institution.